Revenue recognition and accounts receivable (Tables)
|
6 Months Ended |
Jun. 30, 2025 |
|---|
| Revenue Recognition And Accounts Receivable [Abstract] |
|
| Schedule of Net Sales by Product Category by Reporting Segment |
The tables below present net sales by product category by reporting segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2025 |
|
|
2024 |
|
|
Change |
|
Bone Growth Therapies |
|
$ |
62,573 |
|
|
$ |
59,135 |
|
|
|
5.8 |
% |
Spinal Implants, Biologics, and Enabling Technologies |
|
|
107,251 |
|
|
|
108,899 |
|
|
|
-1.5 |
% |
Global Spine |
|
|
169,824 |
|
|
|
168,034 |
|
|
|
1.1 |
% |
Global Orthopedics |
|
|
33,297 |
|
|
|
30,586 |
|
|
|
8.9 |
% |
Net sales |
|
$ |
203,121 |
|
|
$ |
198,620 |
|
|
|
2.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2025 |
|
|
2024 |
|
|
Change |
|
Bone Growth Therapies |
|
$ |
117,623 |
|
|
$ |
111,612 |
|
|
|
5.4 |
% |
Spinal Implants, Biologics, and Enabling Technologies |
|
|
216,037 |
|
|
|
217,715 |
|
|
|
-0.8 |
% |
Global Spine |
|
|
333,660 |
|
|
|
329,327 |
|
|
|
1.3 |
% |
Global Orthopedics |
|
|
63,107 |
|
|
|
57,901 |
|
|
|
9.0 |
% |
Net sales |
|
$ |
396,767 |
|
|
$ |
387,228 |
|
|
|
2.5 |
% |
|
| Schedule of Components Net Sales |
The table below presents product sales and marketing service fees, which are both components of net sales:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Product sales |
|
$ |
191,395 |
|
|
$ |
185,417 |
|
|
$ |
373,028 |
|
|
$ |
361,248 |
|
Marketing service fees |
|
|
11,726 |
|
|
|
13,203 |
|
|
|
23,739 |
|
|
|
25,980 |
|
Net sales |
|
$ |
203,121 |
|
|
$ |
198,620 |
|
|
$ |
396,767 |
|
|
$ |
387,228 |
|
|
| Allowances for Expected Credit Losses |
The following table provides a detail of changes in the Company's allowance for expected credit losses for the three and six months ended June 30, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Allowance for expected credit losses beginning balance |
|
$ |
8,602 |
|
|
$ |
8,398 |
|
|
$ |
7,418 |
|
|
$ |
7,130 |
|
Current period provision for expected credit losses |
|
|
779 |
|
|
|
197 |
|
|
|
1,837 |
|
|
|
1,573 |
|
Write-offs charged against the allowance and other |
|
|
(747 |
) |
|
|
(184 |
) |
|
|
(758 |
) |
|
|
(203 |
) |
Effect of changes in foreign exchange rates |
|
|
275 |
|
|
|
(43 |
) |
|
|
412 |
|
|
|
(132 |
) |
Allowance for expected credit losses ending balance |
|
$ |
8,909 |
|
|
$ |
8,368 |
|
|
$ |
8,909 |
|
|
$ |
8,368 |
|
|